Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2016-02-15 Transaction in Own Shar…
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement detailing the company's stock buyback program, specifically listing the number of shares purchased, average prices, and transaction values over a specific period. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers share repurchases.
2016-02-15 English
Board/Management Information 2016
Board/Management Information Classification · 98% confidence The document text, written in Danish, announces that Eivind Kolding has withdrawn his candidacy for the Novozymes board of directors ahead of the upcoming general meeting on February 24, 2016. It then lists the remaining proposed candidates for re-election and election to the board. This content directly relates to changes in the composition of the board of directors and nominations for the general meeting. This aligns best with the 'Board/Management Information' (MANG) category, as it details changes/nominations for board positions. While it relates to the AGM, the core subject is the board composition change, not the meeting materials (AGM-R) or voting results (DVA).
2016-02-12 Danish
Board/Management Information 2016
Board/Management Information Classification · 99% confidence The document explicitly announces a change regarding a candidate for the Board of Directors: Eivind Kolding will not seek re-election, and the Board proposes a slate of candidates for the upcoming annual shareholders' meeting. This content directly relates to the composition and nomination of the company's governing body. This aligns perfectly with the definition of Board/Management Information (MANG). The document is short and is a direct announcement, not a proxy statement (DEF 14A) or AGM material itself (AGM-R).
2016-02-12 English
Kandidat på valg til bestyrelsen trækker sit kandidatur
Board/Management Information Classification · 92% confidence The document announces that a current board member (Eivind Kolding) will not stand for re-election and proposes new and re-elected candidates to the Board of Directors ahead of the annual shareholders’ meeting. This is a change in the company’s board composition, matching the Board/Management Information category.
2016-02-12 English
Kandidat på valg til bestyrelsen trækker sit kandidatur
Board/Management Information Classification · 100% confidence The document is a company announcement regarding a change in the slate of candidates for the board of directors ahead of an upcoming general meeting. It specifically details the withdrawal of a candidate (Eivind Kolding) and lists the updated board nominations. This falls under the category of announcements concerning changes in the board of directors.
2016-02-12 English
Transaction in Own Shares 2016
Transaction in Own Shares Classification · 100% confidence The document text explicitly states that Novozymes has purchased an accumulated number of shares under a 'stock buyback program' and mentions a total value. This directly relates to the company acquiring its own shares. The filing category 'Transaction in Own Shares' (POS) is the most appropriate fit for reporting share repurchases. Although the text mentions reading the full announcement in PDF format (suggesting RPA/RNS), the core content is a direct report of a transaction (buyback), making POS the primary classification, especially given the very short length which often accompanies these specific transaction reports.
2016-02-08 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.